Deferasirox pharmacokinetics in patients with adequate versus inadequate response

Blood

Volumn 114, Issue 19, 2009, Pages 4009-4013

  Chirnomas, Deborah ^a,b,c   Smith, Amber Lynn ^a   Braunstein, Jennifer ^a   Finkelstein, Yaron ^a,b,d   Pereira, Luis ^a   Bergmann, Anke K ^a,b   Grant, Frederick D ^a,b   Paley, Carole ^e   Shannon, Michael ^a,b   Neufeld, Ellis J ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN;

ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HEMOSIDEROSIS; HEPATOBILIARY SCINTISCANNING; HUMAN; IRON BALANCE; IRON OVERLOAD; IRON TRANSPORT; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; THALASSEMIA;

EID: 77950425913     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-222729     Document Type: Article

References (17)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
2. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with betathalassemia major. Haematologica. 2006;91(10):1343-1351.
3. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462.
4. Metzgeroth G, Dinter D, Schultheis B, et al. Deferasirox in MDS patients with transfusion-caused iron overload: a phase-II study. Ann Hematol. 2009;88(4):301-310.
5. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
6. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597-1602.
7. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111(2):583-587.
8. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436-3441.
9. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood. 1990;76(3):435-444.
10. Olson AD, Hamlin WB. A new method for serum iron and total iron-binding capacity by atomic absorption spectrophotometry. Clin Chem. 1969;15(6):438-444.
11. Rouan MC, Marfil F, Mangoni P, Sechaud R, Humbert H, Maurer G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001;755(1-2):203-213.
12. Séchaud R, Robeva A, Belleli R, Balez S. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol. 2008;48(8):919-925.
13. Torizuka K, Ha-Kawa SK, Kudo M, et al. [Phase III multi-center clinical study on 99mTc-GSA, a new agent for functional imaging of the liver]. Kaku Igaku. 1992;29(2):159-181.
14. McBride KL, Snow K, Kubik KS, et al. Hb Dartmouth [alpha66(E15) Leu→Pro (alpha2) (CTG→CCG)]: a novel alpha2-globin gene mutation associated with severe neonatal anemia when inherited in trans with Southeast Asian alpha-thalassemia-1. Hemoglobin. 2001;25(4):375-382.
15. Ghibellini G, Leslie EM, Pollack GM, Brouwer KL. Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res. 2008;25(8):1851-1860.
16. Séchaud R, Dutreix C, Balez S, et al. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther. 2008;46(2):102-108.
17. Wood J, Thompson AA, Paley C, et al. Deferasirox (Exjade®) monotherapy significantly reduces cardiac iron burden in chronically transfused β-thalassemia patients: an MRI T2* study. Blood (ASH Annual Meeting Abstracts). 2008; 112:Abstract 3882.